Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
@article{Osman2007TamoxifeninducedNS, title={Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?}, author={K. Osman and M. M. Osman and M. Ahmed}, journal={Expert Opinion on Drug Safety}, year={2007}, volume={6}, pages={1 - 4} }
Tamoxifen is a cheap and effective estrogen-receptor antagonist, used as the adjuvant hormonal treatment of choice in women with estrogen-receptor-positive breast cancer. Tamoxifen-induced non-alcoholic steatohepatitis (NASH) may increase the demand on oncologists, not only with regard to screening for diabetes, but also for the suggested link of NASH with high incidence of coronary heart disease. At present, there is no guideline for treatment of hyperlipidaemia associated with tamoxifen… CONTINUE READING
Topics from this paper
38 Citations
Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
- Medicine
- Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
- 2011
- 18
The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer
- Medicine
- Cancer
- 2009
- 61
Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer
- Medicine
- PloS one
- 2020
- PDF
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
- Medicine
- Cancer science
- 2014
- 18
The Relationship Between Tamoxifen‐associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early‐stage Breast Cancer
- Medicine
- Clinical breast cancer
- 2017
- 6
Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.
- Medicine
- World journal of gastroenterology
- 2014
- 59
Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment.
- Medicine
- Journal of hepatology
- 2008
- 17
- PDF
References
SHOWING 1-10 OF 14 REFERENCES
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
- Medicine
- BMJ : British Medical Journal
- 2005
- 169
- Highly Influential
- PDF
CYP17 polymorphism and tamoxifen-induced hepatic steatosis.
- Biology, Medicine
- Hepatology research : the official journal of the Japan Society of Hepatology
- 2005
- 9
Rosuvastatin: A safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH)
- Medicine
- Scandinavian journal of gastroenterology
- 2006
- 10
Serum leptin levels are associated with tamoxifen -induced hepatic steatosis
- Medicine
- Current medical research and opinion
- 2003
- 18
Mitochondrial injury in steatohepatitis
- Medicine
- European journal of gastroenterology & hepatology
- 2004
- 138
Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease
- Medicine
- Journal of Gastroenterology
- 2006
- 455
- PDF
Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States
- Medicine
- Hepatology
- 2006
- 211
Non-alcoholic steatoheptatitis. In: Metabolic Syndrome
- Byrne CD, Wild S (Eds),
- 2005
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease
- Medicine
- Expert opinion on drug safety
- 2006
- 12